Accuray Unveils $55M Recap, Reverse Split, and Tech Partnerships to Reverse Losses
ARAY is trading near its 52-week low of $0.22 (7.0% above the low) on light trading volume (0.3× avg).
Summary
Accuray is taking aggressive steps to stabilize after a brutal Q3. The company announced a $55 million recapitalization with its largest lender and shareholder, TCW, exchanging $40 million of debt for preferred stock convertible at $0.50 per share—a 105% premium to yesterday's close—and injecting $15 million in fresh cash. A reverse stock split is planned to regain Nasdaq compliance, with the ratio to be determined, and financial covenants are waived through 2027, giving management breathing room. Beyond the balance sheet, Accuray signed non-binding letters of intent with Samsung HME America and RaySearch Laboratories to co-develop imaging and adaptive therapy tech, signaling a pivot toward innovation partnerships. The board is shrinking from eight to seven members, with TCW gaining two seats through designees Steven Mayer and Chan Galbato, following the resignations of Beverly Huss and Anne Le Grand, cementing TCW's influence. This follows the May withdrawal of guidance and a delisting warning; today's moves directly address the liquidity and listing crises. The recap and partnerships could mark a turning point if executed, but the reverse split and dilution risk remain key overhangs.
At the time of this announcement, ARAY was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.22 to $2.10. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.